BioSolution Designs (BSD) reported that it is collaborating with RoosterBio to simplify the development and manufacturing of engineered human mesenchymal stem/stromal cell- (MSC) derived therapies.
The partnership leverages BSD’s multigenic design and assembly platform, Bird of Prey, and cell engineering expertise along with RoosterBio’s MSC and exosome bioprocessing products, manufacturing protocols, and analytical services, according to Thomas D. Reed, PhD, CEO of BSD, with the goal of delivering an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.